Renal cell carcinoma.

Journal Article (Journal Article;Review)

Renal cell carcinoma remains a major challenge for urologic oncologists. Over the past year, progress has been made in understanding the molecular biology of this disease and in describing new prognostic factors for outcome following nephrectomy. Studies have better defined patients who might benefit from elective nephron-sparing procedures without increasing the risk of relapse. Combination immunotherapy with interleukin-2 (IL-2) and interferon-alpha appears to be more active than single agent therapy and may be most effective when combined with chemotherapy. No new active chemotherapeutic agents have been identified. Prospective randomized trials suggest that autologous tumor cell vaccines as currently used offer little therapeutic benefit.

Full Text

Duke Authors

Cited Authors

  • Long, GD

Published Date

  • May 1997

Published In

Volume / Issue

  • 9 / 3

Start / End Page

  • 301 - 306

PubMed ID

  • 9229154

International Standard Serial Number (ISSN)

  • 1040-8746

Digital Object Identifier (DOI)

  • 10.1097/00001622-199709030-00014


  • eng

Conference Location

  • United States